Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Patent GmbH | 3,916 |
| 2 | BASF SE | 2,635 |
| 3 | Takeda Pharmaceutical Co Ltd | 2,038 |
| 4 | Merck Sharp and Dohme LLC | 1,967 |
| 5 | Bristol Myers Squibb Co | 1,616 |
| 6 | Bayer CropScience AG | 1,020 |
| 7 | Fujifilm Holdings Corp | 788 |
| 8 | Incyte Corp | 748 |
| 9 | AstraZeneca AB | 729 |
| 10 | Organon Pharma UK Ltd | 525 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07D | Heterocyclic compounds | 34,973 |
| 2 | A61P | Therapeutic activity (drug indications) | 27,627 |
| 3 | A61K | Medicinal preparations | 18,136 |
| 4 | C07C | Acyclic and carbocyclic compounds | 6,371 |
| 5 | A01N | Preservation of bodies; biocides; pest repellents | 5,723 |
| 6 | C09K | Materials for misc. applications | 5,566 |
| 7 | H10K | Organic semiconductors / OLEDs | 4,826 |
| 8 | C07F | Organometallic compounds | 4,705 |
| 9 | Y02E | Climate change mitigation: energy | 4,183 |
| 10 | Y02P | Climate change mitigation: production | 1,800 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Aihua Wang | Johnson & Johnson (United States) | 2 |
| 2 | Alan C. Gibbs | Johnson & Johnson (United States) | 2 |
| 3 | Ellen Sieber-McMaster | Johnson & Johnson (United States) | 2 |
| 4 | Gee‐Hong Kuo | Johnson & Johnson (United States) | 2 |
| 5 | HU Zhi-yong | Johnson & Johnson (United States) | 2 |
| 6 | Hamish Ross | Johnson & Johnson (United States) | 2 |
| 7 | Jolanta Wodzinska | Apotex (Canada) | 2 |
| 8 | Keith T. Demarest | Johnson & Johnson (United States) | 2 |
| 9 | Lan Shen | Johnson & Johnson (United States) | 2 |
| 10 | Lubing Zhou | Johnson & Johnson (United States) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Cu(II)- and Hg(II)-Induced Modulation of the Fluorescence Behavior of a Redox-Active Sensor Molecule | 2001 | 123 | Electrochemical sensors and biosensors |
| 1,2,4-Thiadiazole: A novel Cathepsin B inhibitor | 2003 | 81 | Protease and Inhibitor Mechanisms |
| Synthesis and evaluation of novel dipeptide-bound 1,2,4-Thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase | 2001 | 57 | Blood properties and coagulation |
| A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif | 2007 | 51 | Platelet Disorders and Treatments |
| Investigations on Organo–Sulfur–Nitrogen Rings and the Thiocyanogen Polymer, (SCN)x | 2006 | 29 | Structural and Chemical Analysis of Organic and Inorganic Compounds |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Azosulfime?
Which organizations hold the most patents related to Azosulfime?
What research topics are associated with Azosulfime in the patent literature?
What are the main research applications documented in academic literature?
How has patent activity in this field changed in recent years?